Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulbactam + avibactam
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Sulbactam + avibactam is an experimental, non-commercial antibacterial combination consisting of two small-molecule beta-lactamase inhibitors. Sulbactam is a first-generation beta-lactamase inhibitor that also possesses intrinsic antibacterial activity against Acinetobacter species by targeting penicillin-binding proteins (PBP1a, PBP1b, and PBP3). Avibactam is a diazabicyclooctane (DBO) beta-lactamase inhibitor added to protect sulbactam from enzymatic degradation by beta-lactamases. In vitro studies have shown that the addition of avibactam restores sulbactam's activity against carbapenem-resistant Acinetobacter baumannii (CRAB) isolates, including those producing OXA-type carbapenemases and, in some studies, metallo-beta-lactamases like NDM. The combination is investigated as an off-label or research-use approach for multidrug-resistant or carbapenem-resistant A. baumannii infections, often administered clinically via the co-administration of ampicillin-sulbactam and ceftazidime-avibactam.
- Other names
- sulbactam-avibactamsulbactam/avibactam
02
Targets
PBP2 (Penicillin-binding protein 2)PBP3 (Peptidoglycan D,D-transpeptidase FtsI)Neuraminidaseβ-lactamasePBP1A (Penicillin-binding protein 1A)PBP1b (Penicillin-binding protein 1B)
Beyond the preview
Go deeper on sulbactam + avibactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulbactam + avibactam.